TL;DR
Novartis has secured approval from the Egyptian Drug Authority to use Kisqali for treating early-stage breast cancer. This expands the drug’s indications in Egypt and could impact patient treatment options.
Novartis has received official approval from the Egyptian Drug Authority (EDA) to expand the use of its cancer drug Kisqali for the treatment of early-stage breast cancer, according to reports from Masrawy. This marks a significant regulatory milestone for the pharmaceutical company in Egypt and could influence breast cancer management in the region.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The Egyptian Drug Authority granted approval for Kisqali (ribociclib) to be used as part of a treatment regimen for early-stage breast cancer, a new indication not previously authorized in Egypt. The approval follows data from clinical trials demonstrating Kisqali’s efficacy in early-stage cases, aligning with existing international approvals for advanced breast cancer.
While specific details of the approval process and the clinical data submitted have not been publicly disclosed, sources indicate that the decision was based on robust evidence supporting Kisqali’s safety and effectiveness in early-stage breast cancer patients. The drug, already approved in multiple markets globally, is a CDK4/6 inhibitor that has shown to improve progression-free survival when combined with endocrine therapy.
Novartis has expressed its commitment to expanding access to innovative cancer treatments in Egypt and the broader Middle East region. The company’s local representatives have indicated plans to work with healthcare providers to integrate Kisqali into existing breast cancer treatment protocols, pending further guidance from Egyptian health authorities.
Impact of Kisqali’s New Approval in Egypt
This approval broadens the therapeutic options available for early-stage breast cancer patients in Egypt, potentially improving outcomes through targeted therapy. It also signifies increased regulatory recognition of advanced cancer treatments in the region, which could encourage further approvals and investments. For Novartis, this move strengthens its presence in Egypt’s growing pharmaceutical market and demonstrates confidence in the drug’s global applicability. The development may also influence regional treatment standards, aligning Egypt with international best practices for breast cancer care.Products Worth Considering

Therabody SmartGoggles 2nd Generation Heated Eye and Temple Massager

Oura Ring 5 Smart Ring, Silver, Size 7

Philips Sonicare 7300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
Regulatory Trends and Global Use of Kisqali
Kisqali (ribociclib) has been approved in multiple countries, including the US, EU, and others, primarily for advanced or metastatic breast cancer. Its expansion into early-stage treatment is supported by clinical trials such as MONALEESA-2 and MONALEESA-7, which showed significant benefits in progression-free survival. Egypt’s recent approval aligns with a global trend toward earlier intervention with targeted therapies in breast cancer management. Historically, Egypt’s drug approval process has been evolving, with increasing acceptance of innovative oncology drugs, although local indications often lag behind international approvals. This development reflects both the global shift and Egypt’s efforts to improve cancer care standards.Details of the Approval Process and Clinical Data
It is not yet clear what specific clinical trial data or evidence was submitted to the Egyptian Drug Authority to support the approval. The precise criteria used and whether local or regional studies influenced the decision remain undisclosed. Additionally, how quickly Kisqali will be integrated into standard treatment protocols across Egyptian healthcare facilities is still uncertain.
Next Steps for Kisqali’s Market Introduction in Egypt
Following the approval, Novartis is expected to collaborate with local healthcare providers and authorities to facilitate the drug’s availability. The company may also initiate educational campaigns to inform clinicians about the new indication. Monitoring how quickly Kisqali is adopted into clinical practice and tracking patient outcomes will be key developments in the coming months. Further regulatory updates or approvals for additional indications could also follow, depending on ongoing clinical research and regional health policies.
Key Questions
What is Kisqali used for?
Kisqali (ribociclib) is a targeted cancer therapy primarily used to treat certain types of breast cancer, especially hormone receptor-positive, HER2-negative advanced or metastatic cases. The recent approval expands its use to early-stage breast cancer in Egypt.
How does Kisqali work?
Kisqali is a CDK4/6 inhibitor that blocks specific proteins involved in cancer cell division, slowing or stopping tumor growth when combined with endocrine therapy.
When did Egypt approve Kisqali for this new use?
The approval was announced in March 2024, based on recent reports from Masrawy and official sources.
Will this approval make Kisqali more accessible in Egypt?
Yes, the approval should facilitate wider availability of Kisqali for eligible patients, although actual access depends on distribution, pricing, and healthcare provider adoption.
Are there any safety concerns with Kisqali?
As with all cancer therapies, Kisqali has known side effects, including neutropenia, fatigue, nausea, and liver enzyme elevations. Patients should be monitored closely under medical supervision.
Source: local
